OpenCapital
Beta
Calendar
Stocks
Metrics
Connect AI
/
Stocks
Portfolio
Sign In
Toggle navigation menu
Stocks
Roivant Sciences
Business Segments
Business Segments
Business Segments
16 metrics
Revenue
Cost of revenues
Share-based compensation
Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)
General and administrative (includes $86,874 and $69,386 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $228,778 and $165,670 for the nine months ended December 31, 2025 and 2024, respectively)
Gain on sale of Telavant net assets
Gain (Loss) on Investments
Gain (loss) on fair value of liability instruments
Investment Income, Interest
Other Nonoperating Income (Expense)
Income tax expense (benefit)
Income from discontinued operations, net of tax
Net (loss) income
Acquired in-process research and development
Gain on litigation settlement
Gain on deconsolidation